| Drug Type Fusion protein | 
| Synonyms ZT 003, ZT003 | 
| Target | 
| Action agonists | 
| Mechanism FGF21R agonists, GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Obesity | Phase 1 | Australia  | 09 Oct 2025 | |
| Nonalcoholic Steatohepatitis | IND Approval | United States  | 30 Jun 2025 | |
| Diabetes Mellitus | Preclinical | China  | 14 Jun 2024 | 






